Probiotics Lactobacillus reuteri Abrogates Immune Checkpoint Blockade-Associated Colitis by Inhibiting Group 3 Innate Lymphoid Cells
出版年份 2019 全文链接
标题
Probiotics Lactobacillus reuteri Abrogates Immune Checkpoint Blockade-Associated Colitis by Inhibiting Group 3 Innate Lymphoid Cells
作者
关键词
-
出版物
Frontiers in Immunology
Volume 10, Issue -, Pages -
出版商
Frontiers Media SA
发表日期
2019-06-04
DOI
10.3389/fimmu.2019.01235
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Recent progress in therapeutic antibodies for cancer immunotherapy
- (2018) Anthony Lee et al. CURRENT OPINION IN CHEMICAL BIOLOGY
- Lessons learned from the blockade of immune checkpoints in cancer immunotherapy
- (2018) Xiaolei Li et al. Journal of Hematology & Oncology
- Immune-Related Adverse Events Associated with Immune Checkpoint Blockade
- (2018) Michael A. Postow et al. NEW ENGLAND JOURNAL OF MEDICINE
- The commensal microbiome is associated with anti–PD-1 efficacy in metastatic melanoma patients
- (2018) Vyara Matson et al. SCIENCE
- Role of Lactobacillus reuteri in Human Health and Diseases
- (2018) Qinghui Mu et al. Frontiers in Microbiology
- Divergent Roles of Interferon-γ and Innate Lymphoid Cells in Innate and Adaptive Immune Cell-Mediated Intestinal Inflammation
- (2018) Jennifer Brasseit et al. Frontiers in Immunology
- Checkpoint inhibitor colitis
- (2018) Spyros I. Siakavellas et al. CURRENT OPINION IN GASTROENTEROLOGY
- Lactobacillus reuteri F-9-35 Prevents DSS-Induced Colitis by Inhibiting Proinflammatory Gene Expression and Restoring the Gut Microbiota in Mice
- (2018) Mao-cheng Sun et al. JOURNAL OF FOOD SCIENCE
- Microbiota-Induced TNF-like Ligand 1A Drives Group 3 Innate Lymphoid Cell-Mediated Barrier Protection and Intestinal T Cell Activation during Colitis
- (2018) Jim G. Castellanos et al. IMMUNITY
- Fecal microbiota transplantation for refractory immune checkpoint inhibitor-associated colitis
- (2018) Yinghong Wang et al. NATURE MEDICINE
- Gut microbiome structure and metabolic activity in inflammatory bowel disease
- (2018) Eric A. Franzosa et al. Nature Microbiology
- Characterization of Microbiota in Bronchiectasis Patients with Different Disease Severities
- (2018) Sang Lee et al. Journal of Clinical Medicine
- Bifidobacteriumcan mitigate intestinal immunopathology in the context of CTLA-4 blockade
- (2017) Feng Wang et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Gut microbiome modulates response to anti–PD-1 immunotherapy in melanoma patients
- (2017) V. Gopalakrishnan et al. SCIENCE
- Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors
- (2017) Bertrand Routy et al. SCIENCE
- Burn Injury Leads to Increase in Relative Abundance of Opportunistic Pathogens in the Rat Gastrointestinal Microbiome
- (2017) Guangtao Huang et al. Frontiers in Microbiology
- Lactobacillus reuteri suppresses E. coli O157:H7 in bovine ruminal fluid: Toward a pre-slaughter strategy to improve food safety?
- (2017) Yolande Bertin et al. PLoS One
- Managing Adverse Events With Immune Checkpoint Agents
- (2016) Ramona Dadu et al. CANCER JOURNAL
- The Spectrum and Regulatory Landscape of Intestinal Innate Lymphoid Cells Are Shaped by the Microbiome
- (2016) Meital Gury-BenAri et al. CELL
- Dysregulation of Group 3 Innate Lymphoid Cells in the Pathogenesis of Inflammatory Bowel Disease
- (2016) Marianne Forkel et al. CURRENT ALLERGY AND ASTHMA REPORTS
- Immune-related adverse events with immune checkpoint blockade: a comprehensive review
- (2016) J.M. Michot et al. EUROPEAN JOURNAL OF CANCER
- Lymphoid-Tissue-Resident Commensal Bacteria Promote Members of the IL-10 Cytokine Family to Establish Mutualism
- (2016) Thomas C. Fung et al. IMMUNITY
- Resetting microbiota byLactobacillus reuteriinhibits T reg deficiency–induced autoimmunity via adenosine A2Areceptors
- (2016) Baokun He et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Transient inhibition of ROR-γt therapeutically limits intestinal inflammation by reducing TH17 cells and preserving group 3 innate lymphoid cells
- (2016) David R Withers et al. NATURE MEDICINE
- The future of cancer treatment: immunomodulation, CARs and combination immunotherapy
- (2016) Danny N. Khalil et al. Nature Reviews Clinical Oncology
- Intestinal microbiome analyses identify melanoma patients at risk for checkpoint-blockade-induced colitis
- (2016) Krista Dubin et al. Nature Communications
- Cross-talk between type 3 innate lymphoid cells and the gut microbiota in inflammatory bowel disease
- (2015) Kristine-Ann G. Buela et al. CURRENT OPINION IN GASTROENTEROLOGY
- The biology of innate lymphoid cells
- (2015) David Artis et al. NATURE
- Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma
- (2015) Michael A. Postow et al. NEW ENGLAND JOURNAL OF MEDICINE
- Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy
- (2015) A. Sivan et al. SCIENCE
- Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota
- (2015) M. Vetizou et al. SCIENCE
- Group 3 innate lymphoid cells mediate intestinal selection of commensal bacteria-specific CD4+ T cells
- (2015) M. R. Hepworth et al. SCIENCE
- Baseline circulating IL-17 predicts toxicity while TGF-β1 and IL-10 are prognostic of relapse in ipilimumab neoadjuvant therapy of melanoma
- (2015) Ahmad A. Tarhini et al. Journal for ImmunoTherapy of Cancer
- CX3CR1+mononuclear phagocytes support colitis-associated innate lymphoid cell production of IL-22
- (2014) Randy S. Longman et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Tryptophan Catabolites from Microbiota Engage Aryl Hydrocarbon Receptor and Balance Mucosal Reactivity via Interleukin-22
- (2013) Teresa Zelante et al. IMMUNITY
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
- (2012) Julie R. Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
- (2012) Suzanne L. Topalian et al. NEW ENGLAND JOURNAL OF MEDICINE
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- (2010) F. Stephen Hodi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Lactobacillus reuteri prevents colitis by reducing P-selectin-associated leukocyte- and platelet-endothelial cell interactions
- (2009) O. Schreiber et al. AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started